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One third of all cancer-related deaths worldwide are causedby lung cancer, which accounts for more fatalities each
year than breast, prostate, and colon cancers combined.1
The greatest risk of developing lung cancer is associ-
ated with tobacco use,2 and the World Health Organization
(WHO) estimates that the number of tobacco-related deaths
will have exceeded 2 million per year by 2010.3 Non-small
cell lung cancer (NSCLC) is responsible for 80% of all lung
cancer cases, and most patients present with inoperable lo-
cally advanced (stage III B) or metastatic (stage IV) disease.
Unfortunately, the long-term prognosis for these patients
remains poor because of the inability of systemic therapy to
cure advanced disease. Chemotherapy has only a palliative role
and a 5-year survival rate ranging from 8% to 15%.4Therefore,
active treatment in conjunction with the minimization of side
effects is a key goal.
CHEMOTHERAPY IN ADVANCED DISEASE
In the past few years, several studies have investigated
the use of systemic therapy in this setting. In 1995, the
NSCLC Collaborative Group’s meta-analysis confirmed the
palliative role of chemotherapy.5 The results of 11 random-
ized trials showed that cisplatin-based chemotherapy pro-
duces 10% improvement in 1-year survival compared with
best supportive care alone and determines benefits in terms of
symptom control, quality of life,6 and cost-effectiveness in
advanced NSCLC.7
During the last 10 years, several new cytotoxic agents
have become available; these include taxanes (paclitaxel and
docetaxel), vinorelbine, gemcitabine, and topoisomerase 1
inhibitor irinotecan. Three of these new chemotherapy regi-
mens (gemcitabine plus cisplatin, docetaxel plus cisplatin,
and paclitaxel plus carboplatin) were compared with a reference
doublet (paclitaxel plus cisplatin) in a randomized trial con-
ducted by the Eastern Cooperative Oncology Group (ECOG).
The conclusion was that third-generation agents can moder-
ately improve 1- and 2-year survival rates in patients with
good performance status (PS) with NSCLC. No survival
differences were observed in the four treatment arms, al-
though the carboplatin-containing doublet was associated
with lower toxicity.8
FURTHER AREAS OF INVESTIGATION FOR
CYTOTOXIC AGENTS
The major challenge of future chemotherapy in NSCLC
is the increased efficacy of cytotoxic agents minimizing side
effects. Pemetrexed, a multi-target anti-folate, is a novel drug
recently introduced into clinical practice for the treatment of
malignant pleural mesothelioma9,10 and NSCLC, and it could
play an important role in this setting. The single-agent re-
sponse rates in previously untreated NSCLC are 16% to
23%,11,12 whereas it is 39% to 45% in combination trials.13,14
Trials comparing doublet-containing pemetrexed with
cisplatin plus gemcitabine or with placebo plus best support-
ive care, after prior platinum treatment, are underway. A
comparison between pemetrexed plus cisplatin and a non-
cisplatin–containing arm could also be interesting.15
PHARMACOGENOMICS
Pharmacogenomics makes it possible to select specific
patients on a genetic basis. Early results indicate that the
applications of genomics in NSCLC could have a significant
impact on therapeutic strategies and improve the survival of
particular subpopulations of patients.16
Several studies of pharmacogenomics concern two
genes: RRM1 and ERCC1. RRM1 (ribonucleotide reductase
M1 gene) has an impact on DNA damage and repair. When
this gene is highly expressed, the resistance to gemcitabine is
increased; when the level of RRM1 is low, cell lines become
more sensitive to gemcitabine.17 RRM1 mRNA expression
could be a predictive marker of survival in patients treated
with cisplatin plus gemcitabine, and genetic testing of RRM1
expression could be used to personalize chemotherapy.
Another pharmacogenomic study showed that the ex-
cision repair cross-complementing group (ERCC1) gene is
related to cisplatin activity. A recent phase III trial18 com-
pared docetaxel plus cisplatin versus docetaxel plus gemcit-
abine in stage IV NSCLC and showed that increased ERCC1
mRNA levels are linked with resistance to platinum-based
chemotherapy. Based on the evidence that RRM1 and ERCC1
expression may result in chemoresistence, other trials, like
MADeIT, were initiated. This trial was designed to tailor
chemotherapy based on the expression of these genes. Pa-
tients with high levels of RRM1 expression received a che-
motherapy doublet that did not contain gemcitabine, whereas
those with low levels of RRM1 were treated with gemcitab-
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ine. The goal was to demonstrate that up-front patient selec-
tion can lead to the choice of the appropriate treatment and,
potentially, improve outcome.
BIOLOGICAL AGENTS
Platinum-based combination therapy is the established
standard of care in the treatment of NSCLC; therefore, all
approaches to first-line chemotherapy seem to have reached a
therapeutic plateau. An interesting new field of cancer re-
search is the investigation of novel biological agents able to
target different cell signaling receptors. Because of its central
role in tumor angiogenesis, the vascular endothelial growth
factor (VEGF) and its receptor are very important targets of
biological agents.
Bevacizumab is an anti-VEGF recombinant humanized
monoclonal antibody that can bind and clear VEGF from the
tumor microenvironment.19 It obtains additional antitumor
activity because of its effects on tumor vasculature, intersti-
tial pressure, and blood vessel permeability.20 In NSCLC, the
high expression of VEGF is common and is associated with
poor outcome.21,22 Recent trials23 demonstrated a statistically
significant advantage in median survival favoring the combi-
nation of bevacizumab plus paclitaxel plus carboplatin versus
paclitaxel plus carboplatin in the treatment of advanced
chemotherapy-naı¨ve NSCLC that presented neither hemop-
tysis nor central nervous system metastases. This is the first
trial showing that the addition of a targeted agent to a
standard cytotoxic doublet can prolong survival24 and, in the
United States, this result has led to the use of bevacizumab in
first-line treatment of advanced non-squamous NSCLC. A
study testing two different doses of bevacizumab (7 vs 15
mg/m2) associated with chemotherapy has been completed
recently.
MOLECULAR TARGET THERAPIES
Several targeted agents are being investigated for the
treatment of patients with thoracic malignancies.
ZD6474 is an inhibitor of tyrosin kinase activity of the
VEGF-2 and EGF receptors (EGFR).25
A randomized phase II trial has shown that the addic-
tion of ZD6474 to docetaxel prolongs median time to disease
progression when compared with docetaxel alone.25 This
encouraging result justifies further study in a phase III setting.
Sorafenib is an oral multi-kinase inhibitor that targets
several serine/threonine and receptor tyrosine kinases via its
effects on the RAF/MEK/ERK pathway at the level of Raf
kinase, VEGFR-2 and PDGFR-ß. Several ongoing studies are
evaluating the efficacy of combination chemotherapy with
sorafenib. The clinical benefit of this agent has been demon-
strated in a randomized, double blind, placebo-controlled
phase III study among patients with renal carcinoma (RCC).
Preliminary analyses of the sorafenib monotherapy data in
NSCLC reveal disease-stabilizing effects similar to those
observed in RCC.
However, no benefit was demonstrated in NSCLC with
other biological agents such as bexarotene,26,27 ionafarnib,28
and aprinocarsen,29,30 but negative results could be the result
of lack of selection of patients.
Recent data have suggested that immunotherapy could
have clinical utility in NSCLC. PF-3512676 is a synthetic,
single-stranded oligodeoxynucleotide (ODN) molecule and is
a toll-like receptor 9 (TLR-9) agonist that provides a targeted
and specific modality of immunotherapy by activating plas-
macytoid dendritic cells and B-lymphocytes. Data from a
randomized phase II trial suggest that the addition of PF-
3512676 to standard taxane/platinum chemotherapy for first-
line treatment of patients with advanced NSCLC can increase
objective response rate and prolong overall survival. These
preliminary results indicate that PF-3512676 is able to pro-
vide a novel, safe, and effective treatment modality when
combined with a platinum-based doublet, but confirmatory
phase III trials are necessary.
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